


Review of Products

Sales by product in this fiscal term



Sales of Products in FY2008 (April 2008 - March 2009)

Sales for the fiscal year ended March 2009 totaled ¥136.5 billion, a 6.4% fall of ¥9.3 billion over the previous year.

A review of the performance of major products indicates that *Opalmon® Tablets*, peripheral circulation improving agent, expanded in use in lumber canal stenosis, bringing sales to ¥38.1 billion, increasing ¥0.7 billion (2.0%) year on year.

Onoact® for Injection, a drug for intraoperative and postoperative tachyarrhythmia, received greater appraisal for postoperative indications, resulting in sales of ¥2.7 billion, an increase of ¥0.8 billion (40.5%) over the previous year. *Staybla® Tablets*, a drug for overactive bladder, newly launched in June 2007, made steady market growth and achieved sales of ¥2.2 billion.

Onon® Capsules, a bronchial asthma and allergic rhinitis drug, together with *Onon® Dry Syrup* for the treatment of bronchial asthma, mainly used by pediatric patients, were affected by intensifying competition from competitor products, resulting in Capsules selling ¥24.4 billion, decreasing ¥2.6 billion (9.8%) year on year, and Dry Syrup selling ¥8.9 billion, decreasing ¥2 billion (19.0%) year on year. Despite continuing aggressive efforts to develop its potential market, *Kinedak® Tablets* for the treatment of diabetic peripheral neuropathy suffered from the impact of generic competition and fell in sales, down to ¥15.8 billion, a decrease of ¥1.6 billion (9.2%) over the previous year.

